Prognostic significance of c-erbB-2 protein expression in carcinoma of the cervix treated with radiotherapy.

2.50
Hdl Handle:
http://hdl.handle.net/10541/88041
Title:
Prognostic significance of c-erbB-2 protein expression in carcinoma of the cervix treated with radiotherapy.
Authors:
Nishioka, T; West, Catharine M L; Gupta, Nirmal K; Wilks, Deepti P; Hendry, Jolyon H; Davidson, Susan E; Hunter, Robin D
Abstract:
PURPOSE: The relationship was studied between c-erbB-2 expression and outcome in 107 carcinomas of the cervix treated with radical radiotherapy. METHODS: Formalin-fixed, paraffin-embedded sections were stained by immunohistochemistry for over-expression of the c-erbB-2 protein. A retrospective study of treatment outcome was made on patients with a median follow-up of 55 months. RESULTS: Patients with c-erbB-2-positive tumours had a significantly worse overall survival rate than those with c-crbB-2-negative tumours (P=0.019). Metastasis-free survival (i.e. recurrence outside the radiotherapy field) was also significantly worse (P < 0.001) but there were no differences in local control (i.e. recurrence within the radiotherapy field) rates (P=0.24). Bivariate log-rank analyses showed that the prognostic value of c-erbB-2 expression for metastasis-free survival was independent of disease stage, histological grade, patient age, tumour size and tumour radiosensitivity. A combination of two biological parameters yielded a high discrimination between outcome groups. Women with radiosensitive and c-erbB-2-negative tumours had a 5-year metastasis-free survival level of 70% compared to 33% for women with radioresistant, c-erbB-2-positive tumours. CONCLUSIONS: c-erbB-2 expression is an important prognostic factor for determining tumour recurrence outside the treatment field in cervix carcinomas treated with radiotherapy.
Affiliation:
Department of Clinical Oncology, Christie Hospital (NHS) Trust, Manchester, UK.
Citation:
Prognostic significance of c-erbB-2 protein expression in carcinoma of the cervix treated with radiotherapy. 1999, 125 (2):96-100 J. Cancer Res. Clin. Oncol.
Journal:
Journal of Cancer Research and Clinical Oncology
Issue Date:
1999
URI:
http://hdl.handle.net/10541/88041
DOI:
10.1007/s004320050248
PubMed ID:
10190316
Type:
Article
Language:
en
ISSN:
0171-5216
Appears in Collections:
All Christie Publications ; All Paterson Institute for Cancer Research

Full metadata record

DC FieldValue Language
dc.contributor.authorNishioka, Ten
dc.contributor.authorWest, Catharine M Len
dc.contributor.authorGupta, Nirmal Ken
dc.contributor.authorWilks, Deepti Pen
dc.contributor.authorHendry, Jolyon Hen
dc.contributor.authorDavidson, Susan Een
dc.contributor.authorHunter, Robin Den
dc.date.accessioned2009-12-15T16:39:50Z-
dc.date.available2009-12-15T16:39:50Z-
dc.date.issued1999-
dc.identifier.citationPrognostic significance of c-erbB-2 protein expression in carcinoma of the cervix treated with radiotherapy. 1999, 125 (2):96-100 J. Cancer Res. Clin. Oncol.en
dc.identifier.issn0171-5216-
dc.identifier.pmid10190316-
dc.identifier.doi10.1007/s004320050248-
dc.identifier.urihttp://hdl.handle.net/10541/88041-
dc.description.abstractPURPOSE: The relationship was studied between c-erbB-2 expression and outcome in 107 carcinomas of the cervix treated with radical radiotherapy. METHODS: Formalin-fixed, paraffin-embedded sections were stained by immunohistochemistry for over-expression of the c-erbB-2 protein. A retrospective study of treatment outcome was made on patients with a median follow-up of 55 months. RESULTS: Patients with c-erbB-2-positive tumours had a significantly worse overall survival rate than those with c-crbB-2-negative tumours (P=0.019). Metastasis-free survival (i.e. recurrence outside the radiotherapy field) was also significantly worse (P < 0.001) but there were no differences in local control (i.e. recurrence within the radiotherapy field) rates (P=0.24). Bivariate log-rank analyses showed that the prognostic value of c-erbB-2 expression for metastasis-free survival was independent of disease stage, histological grade, patient age, tumour size and tumour radiosensitivity. A combination of two biological parameters yielded a high discrimination between outcome groups. Women with radiosensitive and c-erbB-2-negative tumours had a 5-year metastasis-free survival level of 70% compared to 33% for women with radioresistant, c-erbB-2-positive tumours. CONCLUSIONS: c-erbB-2 expression is an important prognostic factor for determining tumour recurrence outside the treatment field in cervix carcinomas treated with radiotherapy.en
dc.language.isoenen
dc.subjectCancer Recurrenceen
dc.subjectUterine Cervical Canceren
dc.subject.meshAdenocarcinoma-
dc.subject.meshBrachytherapy-
dc.subject.meshCarcinoma, Squamous Cell-
dc.subject.meshFemale-
dc.subject.meshGene Expression Regulation, Neoplastic-
dc.subject.meshHumans-
dc.subject.meshMiddle Aged-
dc.subject.meshNeoplasm Recurrence, Local-
dc.subject.meshPrognosis-
dc.subject.meshReceptor, erbB-2-
dc.subject.meshRetrospective Studies-
dc.subject.meshSurvival Analysis-
dc.subject.meshTreatment Outcome-
dc.subject.meshUterine Cervical Neoplasms-
dc.titlePrognostic significance of c-erbB-2 protein expression in carcinoma of the cervix treated with radiotherapy.en
dc.typeArticleen
dc.contributor.departmentDepartment of Clinical Oncology, Christie Hospital (NHS) Trust, Manchester, UK.en
dc.identifier.journalJournal of Cancer Research and Clinical Oncologyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.